pharma · Advanced Cancer · Non-small Cell Lung Cancer · RCUS
Arcus Biosciences
Arcus Biosciences patent portfolio — 30 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 3928 Point Eden Way, Hayward, California 94545, US
- Founded
- 2015
- Employees
- 655
- Programs
- 53
- Drugs
- 25
- Patents
- 30
Arcus Biosciences patents
30 pharmaceutical patents indexed for Arcus Biosciences. 0 expire within 24 months.
Arcus Biosciences has 30 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12415854
Antibodies to TIGIT
granted -
US 12410170
2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds
granted -
US 12384773
Thiazole compounds and methods of use thereof
granted -
US 12310965
Treatment of cancer utilizing an identified adenosine fingerprint
granted -
US 12281136
Crystalline forms of a CD73 inhibitor and uses thereof
granted -
US 12226425
Inhibitors of ARG1 and/or ARG2
granted -
US 12195447
Azolopyrimidine for the treatment of cancer-related disorders
granted -
US 12168023
Inhibitors of adenosine 5′-nucleotidase
granted -
US 12103907
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
granted -
US 12071411
Inhibitors of HIF-2α and methods of use thereof
granted -
US 12064433
Pyridone A2R antagonists
granted -
US 12054500
Arginase inhibitors
granted -
US 11993584
Solid forms of an azolopyrimidine compound
granted -
US 11970543
Anti-CD39 antibodies and use thereof
granted -
US 11931343
CD73 inhibitors
granted -
US 11819512
Solid forms of a CD73 inhibitor and the use thereof
granted -
US 11820824
Antibodies to TIGIT
granted -
US 11787762
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
granted -
US 11667662
Modulators of 5′-nucleotidase, ecto and the use thereof
granted -
US 11649261
Crystalline forms of a CD73 inhibitor and uses thereof
granted -
US 11633416
Oral formulations of CD73 compounds
granted -
US 11478479
Dosing with an azolopyrimidine compound
granted -
US 11407712
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
granted -
US 11267845
Inhibitors of CD73-mediated immunosuppression
granted -
US 11058704
Inhibitors of adenosine 5′-nucleotidase
granted -
US 11045472
Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
granted -
US 11001603
Modulators of 5′-nucleotidase, ecto and the use thereof
granted -
US 10981944
Modulators of 5′-nucleotidase, ecto and the use thereof
granted -
US 10399962
Azolopyrimidine for the treatment of cancer-related disorders
granted -
US 10239912
Modulators of 5′-nucleotidase, ecto and the use thereof
granted
Frequently asked questions
How many patents does Arcus Biosciences have?
30 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Arcus Biosciences patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.